Role of FBXW7 in the Quiescence of Gefitinib-Resistant Lung Cancer Stem Cells in EGFR-mutant Non-Small Cell Lung Cancer

Bosnian Journal of Basic Medical Sciences - Bosnia and Herzegovina
doi 10.17305/bjbms.2019.4227
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Association of Basic Medical Sciences of FBIH

Related search

Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

Author Correction: Targeting Hsp90 With FS-108 Circumvents Gefitinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells

Acta Pharmacologica Sinica
MedicinePharmacology
2020English

A Case of Small Cell Lung Cancer Transformation From EGFR-Mutant Lung Adenocarcinoma With Primary Resistance to Gefitinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ERK Inhibition Represses Gefitinib Resistance in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2018English

Inhibition of SREBP Increases Gefitinib Sensitivity in Non-Small Cell Lung Cancer Cells

Oncotarget
Oncology
2016English

Gefitinib Induces Premature Senescence in Non-Small Cell Lung Cancer Cells With or Without EGFR Gene Mutation

Oncology Reports
MedicineCancer ResearchOncology
2007English

Cancer Stem Cells in Lung Cancer: Distinct Differences Between Small Cell and Non-Small Cell Lung Carcinomas

2011English

OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Gefitinib for the Treatment of Non-Small-Cell Lung Cancer

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy